Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy : Prognostic and therapeutic impact on survival

Annals of Surgery

Volumn 260, Issue 5, 2014, Pages 786-793

  Talsma, A Koen ^a   Shapiro, Joel ^a   Looman, Caspar W N ^a   Van Hagen, Pieter ^a   Steyerberg, Ewout W ^a   Van Der Gaast, Ate ^a   Van Berge Henegouwen, Mark I ^b   Wijnhoven, Bas P L ^a   Van Lanschot, J Jan B ^a   Hulshof, Maarten C C M ^b   Van Laarhoven, Hanneke W M ^b   Nieuwenhuijzen, Grard A P ^c   Hospers, Geke A P ^d   Bonenkamp, Johannes J ^e   Cuesta, Miguel A ^f   Blaisse, Reinoud J B ^g   Busch, Olivier R C ^b   Ten Kate, Fiebo J W ^b   Creemers, Geert Jan ^c   Punt, Cornelis J A ^e   Plukker, John T M ^d   Verheul, Henk M W ^f   Van Dekken, Herman ^h   Van Der Sangen, Maurice J C ⁱ   Rozema, Tom ^e   Biermann, Katharina ^a   Beukema, Jannet C ^d   Piet, Anna H M ^f   Van Rij, Caroline M ^a   Reinders, Janny G ^j   Tilanus, Hugo W ^a   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c CATHARINA HOSPITAL   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g RIJNSTATE HOSPITAL   (Netherlands)

^h ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

ⁱ Department of Surgery Radboud University Medical Center ^*  (Netherlands)

^j Radiotherapeutic Institute   (Netherlands)

more..

Author keywords

Chemoradiotherapy; Esophagectomy; Lymph node involvement; Lymphadenectomy; Multimodality treatment

Indexed keywords

CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONFERENCE PAPER; DISEASE ASSOCIATION; DRUG DOSE TITRATION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; ADJUVANT THERAPY; CHEMORADIOTHERAPY; CONTROLLED STUDY; ESOPHAGEAL NEOPLASMS; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84926075845     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000000965     Document Type: Conference Paper

References (29)

1. Rice TW, Zuccaro G, Jr, Adelstein DJ, et al. Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. Ann Thorac Surg. 1998;65:787-792.
2. Prenzel KL, Bollschweiler E, Schroder W, et al. Prognostic relevance of skip metastases in esophageal cancer. Ann Thorac Surg. 2010;90:1662-1667.
3. Altorki N, Kent M, Ferrara C, et al. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg. 2002;236:177- 183.
4. Lerut T, Nafteux P, Moons J, et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: A plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg. 2004;240:962- 972.
5. Jamieson GG, Lamb PJ, Thompson SK. The role of lymphadenectomy in esophageal cancer. Ann Surg. 2009;250:206-209.
6. Tong D, Law S. Extended lymphadenectomy in esophageal cancer is crucial. World J Surg. 2013;37:1751-1756.
7. Peyre CG, Hagen JA, DeMeester SR, et al.The number of lymph nodes removed predicts survival in esophageal cancer: An international study on the impact of extent of surgical resection. Ann Surg. 2008;248:549-556.
8. Rizk NP, Ishwaran H, Rice TW, et al. Optimum lymphadenectomy for esophageal cancer. Ann Surg. 2010;251:46-50.
9. Hulscher JBF, van Sandick JW, de Boer AGEM, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347:1662-1669.
10. Boshier PR, Anderson O, Hanna GB. Transthoracic versus transhiatal esophagectomy for the treatment of esophagogastric cancer: A meta-analysis. Ann Surg. 2011;254:894-906.
11. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366: 2074-2084.
12. Edge S, Byrd BD, Compton CC, et al., eds. American Joint Committee on Cancer Staging Manual. 7th ed. New York: Springer-Verlag; 2009.
13. Shapiro J, ten Kate FJ, van Hagen P, et al. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa. Ann Surg. 2013;258:678-688.
14. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103:1347-1355.
15. Schneider PM, Baldus SE, Metzger R, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg. 2005;242:684-692.
16. Vallböhmer D, Hölscher AH, DeMeester S, et al. A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer. Ann Surg. 2010;252:744-749.
17. Donohoe CL, O'Farrell NJ, Grant T, et al. Classification of pathologic response to neoadjuvant therapy in esophageal and junctional cancer: Assessment of existing measures and proposal of a novel 3-point standard. Ann Surg. 2013;258:784-792.
18. Izbicki JR, Hosch SB, Pichlmeier U, et al. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med. 1997;337:1188-1194.
19. Waterman TA, Hagen JA, Peters JH, et al. The prognostic importance of immunohistochemically detected node metastases in resected esophageal adenocarcinoma. Ann Thorac Surg. 2004;78:1161-1169.
20. Bilchik AJ, Hoon DS, Saha S, et al. Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. Ann Surg. 2007;246:568-575.
21. Mariette C, Piessen G, Briez N, Triboulet JP. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg. 2008;247:365-371.
22. Solomon N, Zhuge Y, Cheung M, et al. The roles of neoadjuvant radiotherapy and lymphadenectomy in the treatment of esophageal adenocarcinoma. Ann Surg Oncol. 2010;17:791-803.
23. Torgersen Z, Sundaram A, Hoshino M, et al. Prognostic implications of lymphadenectomy in esophageal cancer after neo-adjuvant therapy: A single center experience. J Gastrointest Surg. 2011;15:1769-1776.
24. Chao YK, Liu HP, Hsieh MJ, et al. Impact of the number of lymph nodes sampled on outcome in ypT0N0 esophageal squamous cell carcinoma patients. J Surg Oncol. 2012;106:436-440.
25. Sisic L, Blank S, Weichert W, et al. Prognostic impact of lymph node involvement and the extent of lymphadenectomy (LAD) in adenocarcinoma of the esophagogastric junction (AEG). Langenbecks Arch Surg. 2013;398:973-981.
26. Shridhar R, Hoffe SE, Almhanna K, et al. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy. Ann Surg Oncol. 2013;20:3038- 3043.
27. Wang D, Smit JK, Zwaan E, et al. Neoadjuvant therapy reduces the incidence of nodal micrometastases in esophageal adenocarcinoma. Am J Surg. 2013;206:732-738.
28. Herbella FA, Laurino Neto RM, Allaix ME, Patti MG. Extended lymphadenectomy in esophageal cancer is debatable. World J Surg. 2013;37:1757-1767.
29. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985;312:1604-1608.